Human minor vault protein p193

Details Human minor vault protein p193 Human minor vault protein p193

2000-06-28

2003-04-29

Caputa, Anthony C. (Department: 1642)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Using a micro-organism to make a protein or polypeptide

C435S069100, C435S069300, C435S070100, C435S325000, C435S320100, C536S023500, C536S023100, C536S025100

Reexamination Certificate

active

06555347

ABSTRACT:

BACKGROUND
Cancer is a major cause of morbidity and mortality in the United States. Treatment of cancer generally includes chemotherapy, radiation therapy and surgery. Unfortunately, most cancers cannot be cured using chemotherapy because tumor cells tend to develop resistance to several chemotherapeutic agents over time. These cancers are referred to as “multidrug-resistant cancers” (MDR).
Overexpression of a number of proteins has been found to be associated with MDR cells lines, including P-glycoprotein (Pgp) and multidrug resistance-associated protein (MRP). These proteins appear to mediate drug resistance by acting as cytotoxic drug efflux pumps. However, many MDR cancer cell lines are known which are not associated with overexpression of either P-glycoprotein or multidrug resistance-associated protein.
More recently, a protein has been described that is overexpressed in MDR tumor cell lines which do not overexpress either P-glycoprotein or multidrug resistance- associated protein. This protein was originally named Lung Resistance-related Protein (LRP), referring to the cell line in which it was originally identified. However, once the cDNA for Lung Resistance-related Protein was isolated and the corresponding protein sequence elucidated, it was found that Lung Resistance-related Protein was human major vault protein, a previously known protein.
Vaults are large, barrel-shaped, multi-subunit, cytoplasmic, ribonucleoprotein organelles found in virtually all higher organisms and in most normal tissues. Mammalian vaults consist of three proteins having molecular weights of approximately 210, 193 and 104, and a small RNA in the relative molar ratios of 1:1:24:4 in rats. The most abundant of these, the 104 kDa protein, is termed major vault protein (MVP) and corresponds to the Lung Resistance-related Protein. The minor vault protein p193, however, has not yet been characterized.
Therefore, there remains a need for chemotherapeutic agents that will target multidrug-resistant cancers. Further, there remains a need to characterize the minor vault protein p193.
SUMMARY
According to one embodiment of the present invention, there is provided apolynucleotide molecule encoding human minor vault protein p193, or its complementary strands, and a polynucleotide molecule which hybridizes to such a polynucleotide sequence. According to another embodiment of the present invention, there is provided a vector containing such a polynucleotide and a prokaryotic or eukaryotic host cell stably transformed or transfected by the vector.
According to yet another embodiment of the present invention, there is provided a polynucleotide molecule according to SEQ ID NO: 1, or its complementary strands, and a polynucleotide molecule which hybridizes to such a polynucleotide sequence. According to another embodiment of the present invention, there is provided a vector containing such a polynucleotide and a prokaryotic or eukaryotic host cell stably transformed or transfected by the vector.
According to still another embodiment of the present invention, there is provided a purified and isolated polynucleotide molecule consisting essentially of a nucleotide sequence encoding human minor vault protein p193, or its complementary strands, or a combination of a nucleotide sequence encoding human minor vault protein p193 and its complementary strands, as well as a polynucleotide molecule which hybridizes to such a polynucleotide sequence. According to another embodiment of the present invention, there is provided a vector containing such a polynucleotide and a prokaryotic or eukaryotic host cell stably transformed or transfected by the vector.
Additionally, there is provided a method of making human minor vault protein p193, comprising culturing a microorganism transformed with a polynucleotide according to the present invention; and recovering the human minor vault protein pl93.
FIGURES
These and other features, aspects and advantages of the present invention will become better understood with regard to the following description, appended claims, and accompanying figures where:
FIGS. 1
a
-
1
i
show the complete sequence of cDNA encoding human minor vault protein 193 and its complementary strand, where the top strand is SEQ ID NO: 1; and
FIG. 2
shows the complete amino acid sequence of human minor vault protein p193 (SEQ ID NO: 2) indicating specific regions of function.


REFERENCES:
Kickhoefer, V.A. et al. The 193-kD vault porotein, VPARP, is a novel poly(ADP-ribose) polymerase. J. Cell Biology, 146(5): 917-928, 1999.*
Accession No. N78296, Database GenBank EST, Hillier, L. et al. Genome Res. 6(9): 807-828, 1996.*
Accession No. AA034060, Database GenBank EST, Hillier, L. et al., Genome Res. 6(9): 807-828, 1996.*
Accession No. AA622038, Database GenBank EST, NCI-CGAP, Oct. 14, 1997.*
Accession No. AA52384, Database GenBank EST, NCI-CGAP, Aug. 5, 1997.*
Sambrook, J. et al. Molecular Cloning, A Laboratory Manual, 2ndEdition, Cold Spring Harbour Laboratory Press, 1989, pp. 16.3, 16.4, 16.17-16.22, 16.28, 16.29, and 17-38-17.41.*
Bork, Peer et al., “A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins,”The Faseb Journal, 11:68-76, 1997.
Callebaut, Isabelle et al., “From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair,”FEBS Letters, 400:25-30, 1997.
Database GenBank, Accession No. D79999, Nomura, N., Human mRNA for K1AA0177 gene, partial cds. DDBJ/EMBL/, see entire file.
Golemis, Erica A. et al., “Interaction Trap/Two-Hybrid System to Identify Interacting Proteins,”Current Protocols in Mol. Biol., 20.1.1-20.35, John Wiley & Sons, 1997.
Hart, S.M. et al., “Expression of the human major vault protein LRP in acute myeloid leukemia,”Experimental Hematology, 25(12):1227-1232, Nov. 1997.
Inman, E.M. et al., “Targeted Degradation of the Vault RNA (vRNA) in vivo Using Antisense Oligodeoxynucleotides,”Molecular Biology of the Cell, vol. 6, Suppl., p. 196a.
Izquierdo, M.A. et al., “Relationship of LRP-human major vault protein to in vitro and clinical resisttance to anticancer drugs,”Cytotechnology, 19(3):191-197, 1996.
Kedersha, Nancy L. et al., “Vaults.III.Vault Ribonucleoprotein Particles Open into Flower-like Structures with Octagonal Symmetry,”The Journal of Cell Biology, 112(2):225-235 (1991).
Kickhoefer, V. et al., “Multidrug resistant cancer cell lines contain elevated levels of vaults,”Proc. Amer. Assoc. Cancer Res., Mar. 1997, p. 252, Abstract #1694.
Kickhoefer, V.A. et al., “Vault Ribonucleoprotein Particles from Rat and Bullfrog Contain a Related Small RNA That Is Transcribed by RNA Polymerase III,”The Journal of Biological Chemistry, 268(11):7868-7873, Apr. 15, 1993.
Kickhoefer, Valerie A. et al., “Vaults are the answer, what is the question?”Trends in Cell Biology, 6:174-178 1996.
Kickhoefer, V. et al., “Vaults Are Up-regulated in Multidrug-resistant Cancer Cell Lines,”J. Biol. Chem., Apr. 10, 1998, vol. 273(15):8971-8974.
Kim, K. et al., “Tumor Suppressor Gene Expression during Normal and Pathologic Myocardial Growth,”J. Biol. Chem., 269(36):22607-22613, Sep. 9, 1994.
Nagase, Takahiro et al., “Prediction of the Coding Sequences of Unidentified Human Genes,”DNA Research, 3:17-24 1996.
Ruf, Armin et al., “Structure of the catalytic fragment of poly(ADP-ribose) polymerase from chicken,”Proc. Natl. Acad. Sci. USA93:7481-7485 1996.
Scheffer, George L. et al., “The drug resistance-related protein LRP is the human major vault protein,”Natire Medicine, 1(6):578-582 1995.
Sebolt-Leopold, Jr. et al., “Enhancement of Alkylating Agent Activity in vitro by PD 128763, a Potent Poly(ADP-ribose) Synthetase Inhibitor,”Int. J. Radiation Oncology Biol. Phys., 222:619-621 1992.
Simonin, Frederic et al., “The Carboxyl-terminal Domain of Human Poly(ADP-ribose) Polymerase,”The Journal of Biological Chemistry, 268(18):13454-13461 1993.
Kedersha, N.L. et al, “Vaults. II. Ribonucleoprotein Structures Are Highly Conserved Among Higher and Lower Eukaryotes,”J. Cell Biol., 110:895-901 (Apr. 1990).
Kickhoefer, Valerie A. et al., “The 193-kD Vault Protein, VPARP, Is

Affiliated with

Also associated with

Rating

Human minor vault protein p193 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Human minor vault protein p193, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human minor vault protein p193 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3060483